BSA载药微囊的制备、表征及体外释放行为

采用复乳法-液中干燥法制备了一系列含有牛血清蛋白(BSA)的聚乙二醇-b-聚(6-(乙酸苄酯)-ε-己内酯-co-ε-己内酯(PEBCL)微囊.分别研究了聚合物结构以及制备条件对微囊粒径、载药量和包封率的影响,同时研究了载药微囊在pH=7.4的磷酸盐缓冲溶液中的体外释放行为.研究表明:微囊的平均粒径13～30 μm,微囊对BSA的载药量和包封率分别最高可以达到14.18%和75.90%,药物的释放行为可控,PEBCL微囊作为蛋白质类药物载体有望在临床上获得应用.     

磁性微胶囊的制备及其药物缓控释性能

用乳液-凝胶法制备了磁性壳聚糖/海藻酸钠微胶囊. 在壳聚糖/海藻酸钠微胶囊中掺入Fe3O4磁性中空球, 使微胶囊具有磁靶向性能. 以头孢拉定作为模型药物研究了载药磁性微胶囊的载药量、包封率及药物缓控释性能等. 结果表明, 提高头孢拉定的初始浓度可以提高载药量, 却不利于提高药物的包封率. 所制备的微胶囊在各种缓冲溶液中长时间内具有显著的缓释效果, 并具有pH 刺激响应释放的性能, 即在模拟胃液中的药物释放率大大降低, 而在模拟体液和肠液中的释放时间大大延长, 可达50 h以上. 另外, 在外加磁场作用下, 微胶囊表现出良好的磁定向运动性能, 为磁靶向药物输送提供基础.     

同源细胞膜包覆智能释药纳米粒用于肝癌靶向治疗

近年来,纳米药物递送系统在癌症治疗方面的应用受到广泛关注。 传统的纳米药物递送系统存在生物相容性差、靶向性缺乏、在肿瘤部位释药缓慢等问题。 本文设计制备了一种同源细胞膜(M)包覆、癌细胞还原微环境控制释药的脂质体纳米粒子(命名为P-ss-G/D/Sf@M)来递送肝癌治疗药物索拉非尼(Sf)用于肝癌的靶向治疗。 利用薄膜水化法结合静电吸附及过膜挤压法制备包覆细胞膜的空白(P-ss-G/D@M)及载药(P-ss-G/D/Sf@M)纳米粒子。 P-ss-G/D/Sf@M对Sf的载药量为7.2%,包封率为79.9%。 体外释药结果显示,P-ss-G/D/Sf@M在还原条件下会加快药物的释放,48 h时药物释放量达到65%以上,较非还原条件下释药量提高了25%。 体外细胞实验结果证明,包覆肝癌细胞膜的纳米粒子更易被肝癌细胞摄取,表现了对肝癌细胞的靶向性,同时在肿瘤细胞高浓度谷胱甘肽(GSH)还原环境作用下,纳米粒子中的二硫键断裂,迅速释放药物,与非还原敏感载药纳米粒子相比,显著抑制肝癌细胞生长,提高细胞凋亡率。 因此,本文制备的同源细胞膜包覆的智能释药载体有可能用于今后的癌症治疗中。     

基于壳聚糖衍生物的蛋白质药物载体材料的制备及性能

在离子液体均相体系中合成了一种新型两亲性窄分子量分布的低聚壳聚糖衍生物月桂基-琥珀酰化壳聚糖(LSCOS). 以LSCOS为载体材料, 以牛血清蛋白(BSA)为模板蛋白, 以戊二醛为交联剂, 用油包水(W/O)乳化交联法制备了包载BSA的BSA/LSCOS缓释载药微球. 通过扫描电子显微镜(SEM)、 透射电子显微镜(TEM)及紫外-可见光谱(UV-Vis)研究了BSA/LSCOS比率和戊二醛/LSCOS比率对微球的形貌结构、 包埋率、 载药率和体外药物释放特性的影响. 结果表明, 在离子液体中合成的LSCOS包覆了BSA, 形成的微球粒径约为1 μm, 微球表面随BSA用量的增加变得光滑, 随戊二醛用量的增加变得粗糙. BSA的累积释放率与BSA包载量成正比, 与交联剂添加量成反比, 因此, 可通过控制蛋白质药物的添加比率和交联剂用量来控制蛋白质药物体外释放率.     

普鲁兰多糖的硬脂酸修饰及其作为纳米药物载体的研究

利用1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和4-二甲氨基吡啶(DMAP)催化硬脂酸(SA)与具有良好生物相容性的普鲁兰多糖(Pullulan)反应, 将硬脂酸接枝在普鲁兰分子链的羟基上, 得到取代度不同的疏水改性两亲性普鲁兰多糖衍生物PUSA1, PUSA2 及PUSA3, 其临界胶束浓度分别为50, 32, 18 μg/mL; 透射电镜(TEM)图像显示透析法制备的PUSA 自组装颗粒为球形. 以阿霉素为模型药物制备了PUSA 载药纳米粒, 考察了载药纳米粒的载药量、包封率和体外药物释放. 结果表明PUSA3 的包封率高达84%, 载药量达7.79%. 药物可在37 ℃, pH＝7.4 的PBS 溶液中持续释放90 h 以上. 细胞毒性实验(MTT)结果显示当PUSA 的浓度高达1000 μg/mL 时48 h 后细胞存活率依然在90%左右. 流式细胞及荧光分析表明载药纳米粒的细胞摄取率远远高于游离药物. 说明PUSA 是一种新型的有潜在应用价值的药物载体材料.     

微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

顺铂温敏载药粒子的制备表征

制备了顺铂温敏载药纳米粒子，表征其相关性质并考察不同温度下对体外肿瘤细胞的生长抑制作用。制备的两亲嵌段聚合物在水溶液中自发形成胶束结构并包裹顺铂，测定顺铂载药粒子的结构、形态、粒径及包封率、载药量、晶体状态等特性，并对顺铂的体外释放以及不同细胞系体外毒性也做了研究。载药粒子粒径为83.3 ± 4.3 nm，载药量为37.8%，包封率为77.8%。血清中相变温度39.3 ℃。载药颗粒在单纯化疗时细胞抑制率较小，加热后抑制作用明显增加(P<0.01)，与游离药物相近(P>0.5)。顺铂载药纳米粒子具有较好的温控特性，为顺铂在肿瘤热靶向治疗中的应用提供了一条新的途径。     

PVP-semi-IPN-PCL/PLA水凝胶制备及负载卡马西平药物共晶体外释放

通过N-乙烯基吡咯烷酮(N-vinyl pyrrolidone, NVP)在聚己内酯(polycaprolactone, PCL)、聚乳酸(poly(lactic acid),PLA)乙酸乙酯溶液中自由基聚合,制得聚乙烯吡咯烷酮(Polyvinylpyrrolidone, PVP)/聚己内酯、聚乳酸半互穿网络(semi-interpenetrating network, semi-IPN)水凝胶(PVP-semi-IPN-PCL/PLA)。实验制得疏水/亲水比例分别为1∶9、3∶7、5∶5的三种水凝胶。采用溶剂挥发法制备卡马西平-丁二酸药物共晶(carbamazepine-succinic acid, CBZ-SUC)。使用PVP-semi-IPN-PCL/PLA负载CBZ-SUC共晶,考察上述三种凝胶药物载体的载药能力及体外释放行为。使用1∶9、3∶7、5∶5比例凝胶制备了载药量分别为17%、19%、21%,包封率分别为71%、83%、89%的载药凝胶,其在37℃,pH=6.8 PBS溶液中体外释放效果均优于未使用凝胶载体的CBZ-SUC共晶。其中,3∶7组载药凝胶的累积释放量最高,...     

含水核载牛血清白蛋白聚氰基丙烯酸丁酯微囊的制备及体外释放

利用界面乳液聚合方法制备了新型含水核载牛血清白蛋白 (BSA)的聚氰基丙烯酸丁酯 (PBCA)纳米微囊 .分别研究了纳米微囊的粒径及其分布 ,表面Zeta电势的变化 .并以牛血清白蛋白为模型药物考察了药物包裹率和载药量的变化以及载药纳米微囊在磷酸缓冲溶液中的体外释放行为 .结果表明 ,所制备的纳米微囊平均粒径为 2 0 0nm ,多分散度为 0 2 2 6;表面Zeta电势的变化证明了BSA是包裹于纳米微囊的内部而不是吸附在其表面 ;包裹率和载药量取决于水相中BSA的初始浓度 ,当BSA的浓度为 0 8mg mL时 ,包裹率和载药量分别为 3 5 %和 0 485× 1 0 - 9mol mg;药物的释放速率取决于纳米微囊的壁厚 ,通过调节壁厚可以达到控释的目的     

双重载药多层海藻酸盐-壳聚糖缓释微球的制备及体外释放

采用滴注法将海藻酸钠与钙离子交联,制成负载血管内皮生长因子(VEGF)的藻酸钙核心球,利用层层自组装技术在核心球的表面依次包覆壳聚糖、海藻酸和壳聚糖,壳聚糖中负载万古霉素(VAN),形成多药载药缓控体系.采用正交实验考察海藻酸钠浓度、钙离子浓度及壳聚糖浓度对VEGF和VAN的药物包封率和载药量的影响,优化了制备工艺.采用扫描电子显微镜观察多层微球的表面、截面形貌及粒径,采用傅里叶变换红外光谱检测海藻酸盐与壳聚糖的自组装情况,分别采用酶联免疫吸附(ELISA)双抗体夹心法和紫外分光光度法检测VEGF和VAN的包封率、载药量及体外释放情况.结果表明,海藻酸钠最优浓度为0.04g/mL,氯化钙最优浓度为0.15g/mL,壳聚糖最优浓度为0.01g/mL.微球光滑圆整,均质实心,直径900~1100μm,VEGF的包封率达61.31%,VAN的包封率为3.48%.体外释放实验结果表明,VEGF缓释时间为15.5d,并出现2个释放高峰;VAN缓释时间为4.5d,释药情况平稳持续,无明显突释.双重载药多层包覆微球兼具控制感染和促进血管生成两种潜能,有望应用于组织工程骨的基础研究和临床实践.     

PLGA/TiO2纳米药物缓释载体的研究

首先利用硅烷偶联剂(KH550)对纳米二氧化钛表面进行预处理,得到氨基改性的二氧化钛,然后与带有高活性端基的丙交酯-乙交酯共聚物(PLGA)反应,制备纳米药物缓释载体PLGA/TiO2有机-无机杂化材料.通过核磁(1H-NMR)、傅里叶变换红外光谱仪(FTIR)、热重分析(TGA)、扫描电子显微镜(SEM)、透射电子显...     

Preparation of PLGA microspheres with different porous morphologies

Poly(D,L-lactide-co-glycolide)(PLGA) microspheres were prepared by emulsion solvent evaporation method. The influences of inner aqueous phase, organic solvent, PLGA concentration on the morphology of microspheres were studied. The results showed that addition of porogen or surfactants to the inner aqueous phase, types of organic solvents and polymer concentration affected greatly the microsphere morphology. When dichloromethane was adopted as organic solvent, microspheres with porous structure were produced. When ethyl acetate served as organic solvent, two different morphologies were obtained. One was hollow microspheres with thin porous shell under a lower PLGA concentration, another was erythrocyte-like microspheres under a higher PLGA concentration. Three types of microspheres including porous, hollow core with thin porous shell(denoted by hollow in brief) and solid structures were finally selected for in vitro drug release tests. Bovine serum albumin(BSA) was chosen as model drug and encapsulated within the microspheres. The BSA encapsulation efficiency of porous, hollow and solid microspheres was respectively 90.4%, 79.8% and 0. And the ultimate accumulative release was respectively 74.5%, 58.9% and 0. The release rate of porous microspheres was much slower than that of hollow microspheres. The experiment results indicated that microspheres with different porous structures showed great potentials in controlling drug release behavior.     

Preparation of uniform-sized pH-sensitive quaternized chitosan microsphere by combining membrane emulsification technique and thermal-gelation method

In this study, uniform-sized pH-sensitive quaternized chitosan microsphere was prepared by combining Shirasu porous glass (SPG) membrane emulsification technique and a novel thermal-gelation method. In this preparation process, the mixture of quaternized chitosan solution and alpha-beta-glycerophosphate (alpha-beta-GP) was used as water phase and dispersed in oil phase to form uniform W/O emulsion by SPG membrane emulsification technique. The droplets solidified into microspheres at 37 degrees C by thermal-gelation method. The whole process was simple and mild. The influence of process conditions on the property of prepared microspheres was investigated and the optimized preparation condition was obtained. As a result, the coefficient of variation (C.V.) of obtained microspheres diameters was below 15%. The obtained microsphere had porous structure and showed apparent pH-sensitivity. It dissolved rapidly in acid solution (pH 5) and kept stable in neutral solution (pH 7.4). The pH-sensitivity of microspheres also affected its drug release behavior. Bovine serum albumin (BSA) as a model drug was encapsulated in microspheres, and it was released rapidly in acid solution and slowly in neutral medium. The novel quaternized chitosan microspheres with pH-sensitivity can be used as drug delivery system in the biomedical field, such as tumor-targeted drug carrier.     

A detailed view of PLGA-mPEG microsphere formation by double emulsion solvent evaporation method

PLGA, m PEG diblock copolymer was synthesized by bulk ring-opening polymerization method. The double emulsion solvent evaporation method was used to prepare bovine serum albumin(BSA)-loaded microspheres. Optical microscopy was used to observe the whole microsphere fabrication process. It is confirmed that the proportion of inner aqueous phase is one of the most critical factors that determines the morphology of microspheres. Double emulsion droplets which have appropriate amount of inner aqueous phase can form closed and dense microspheres, while, too much inner aqueous phase will cause a collapse of the double emulsion droplets, resulting in a loss of drug. The proportion of inner aqueous phase was varied to prepare microspheres of different morphology. The results show that with increasing the amount of inner aqueous phase, a higher percent of broken microspheres and lower encapsulation efficiency appeared, and also, a more severe initial burst release and faster release rate.     

Bovine Serum Albumin Loaded Solid Lipid Nanoparticles Prepared by Double Emulsion Method

Solid lipid nanoparticles loaded with bovine serum albumin(BSA) were prepared by a double emulsion method. As the mass fraction of the model drug BSA increased from 0 to 15%, the particle size gradually increased. The physical stability of the nanoparticles was investigated by zeta potential measurement and they were shown to be quite stable. Fluorescence spectroscopy confirmed that the loaded position of BSA was on the interface between the inner aqueous phase and the solid lipid phase. Both Fourier-transf...     

Encapsulation and release of biomolecules from Ca-P/PHBV nanocomposite microspheres and three-dimensional scaffolds fabricated by selective laser sintering

This study focused on the fabrication of calcium phosphate (Ca-P)/poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) nanocomposite scaffolds loaded with biomolecules using the selective laser sintering (SLS) technique and their evaluation. Ca-P/PHBV nanocomposite microspheres loaded with bovine serum albumin (BSA) as the model protein were fabricated using the double emulsion solvent evaporation method. The encapsulation efficiency of BSA in PHBV polymer microspheres and Ca-P/PHBV nanocomposite microspheres were 18.06 ± 0.86% and 24.51 ± 0.60%, respectively. The BSA loaded Ca-P/PHBV nanocomposite microspheres were successfully produced into three-dimensional porous scaffolds with good dimensional accuracy using the SLS technique. The nanocomposite microspheres served as protective carriers and maintained the bioactivity of BSA during SLS. The effects of SLS parameters such as laser power and scan spacing on the encapsulation efficiency of BSA in the scaffolds and in vitro BSA release were studied. An initial burst release was observed, which was followed by a slow release of BSA. After 28-day release, The PHBV matrix was slightly degraded after 28-day in vitro release study. It was shown that nanocomposite scaffolds with controlled architecture obtained via SLS could be incorporated with biomolecules, enhancing them with more functions for bone tissue engineering application or making them suitable for localized delivery of therapeutics.     

Preparation of chitosan microspheres by ionotropic gelation under a high voltage electrostatic field for protein delivery

Biodegradable microspheres have been widely used in drug/protein delivery system. In this paper, a modified ionotropic gelation method combined with a high voltage electrostatic field was developed to prepare protein-loaded chitosan microspheres. Bovine serum albumin (BSA) was chosen as a model protein. The preparation process and major parameters were discussed and optimized. The morphology, particle size, encapsulation efficiency and in vitro release behavior of the prepared microspheres were investigated. The results revealed that the microspheres exhibited good sphericity and dispersity when the mixture of sodium tripolyphosphate (TPP) and ethanol was applied as coagulation solution. Higher encapsulation efficiency (>90%) was achieved for the weight ratio of BSA to chitosan below 5%. 35% of BSA was released from the microspheres cured in 3% coagulation solution, and more than 50% of BSA was released from the microspheres cured in 1% coagulation solution at pH 8.8. However, only 15% of BSA was released from the microspheres cured in 1% coagulation solution at pH 4. The results suggested that ionotropic gelation method combined with a high voltage electrostatic field will be an effective method for fabricating chitosan microspheres for sustained delivery of protein.     

磁性壳聚糖微球对牛血清白蛋白的吸附性能

在微乳液体系中, 以戊二醛为交联剂制备了磁性壳聚糖纳米粒子(Fe₂O₃-CS). 采用透射电子显微镜(TEM)、红外光谱(IR)、振动样品磁强计(VSM)等手段对纳米粒子进行表征. 结果表明, 纳米粒子的粒径在40 nm左右, 分散性良好, 具有较好的磁响应性能. 以碳二亚胺(EDC)为活化剂, 研究了Fe₂O₃-CS纳米粒子对牛血清白蛋白(BSA)分子的吸附性能, 并使用原子力显微镜(AFM)、紫外分光光度计(UV)进行表征. Fe₂O₃-CS粒子对BSA 的吸附大致符合Langmuir吸附模型, 298 K时饱和吸附量约为250 mg·g^-1, 吸附常数为0.007 L·mg^-1. 将BSA-粒子分散在不同pH的缓冲溶液中, 研究BSA-粒子复合物的稳定性. 用聚丙烯酰氨凝胶电泳(SDS-PAGE)对结果进行表征, 发现在碱性条件下BSA分子能从磁性粒子表面脱附下来.     

Preparation and Characterization of a Novel Drug Delivery System: Biodegradable Nanoparticles in Thermosensitive Chitosan/Gelatin Blend Hydrogels

A novel injectable in situ gelling drug delivery system (DDS) consisting of biodegradable N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride (HTCC) nanoparticles and thermosensitive chitosan/gelatin blend hydrogels was developed for prolonged and sustained controlled drug release. Four different HTCC nanoparticles, prepared based on ionic process of HTCC and oppositely charged molecules such as sodium tripolyphosphate, sodium alginate and carboxymethyl chitosan, were incorporated physically into thermosensitive chitosan/gelatin blend solutions to form the novel DDSs. Resulting DDSs interior morphology was evaluated by scanning electron microscopy. The effect of nanoparticles composition on both the gel process and the gel strength was investigated from which possible hydrogel formation mechanisms were inferred. Finally, bovine serum albumin (BSA), used as a model protein drug, was loaded into four different HTCC nanoparticles to examine and compare the effects of controlled release of these novel DDSs. The results showed that BSA could be sustained and released from these novel DDSs and the release rate was affected by the properties of nanoparticle: the slower BSA release rate was observed from DDS containing nanoparticles with a positive charge than with a negative charge. The described injectable drug delivery systems might have great potential application for local and sustained delivery of protein drugs.     

种子乳胶粒表面修饰法制备核壳结构PSt/TiO_2复合微球

首先采用无皂乳液聚合法合成了表面带负电荷、粒径为360 nm的单分散聚苯乙烯(PSt)乳液,并利用聚乙烯亚胺(PEI)在25℃下对PSt乳胶粒表面进行修饰,得到了表面带有正电荷的PSt种子乳液;然后以乙醇和水的混合物为反应介质,采用种子乳液加入法,使钛酸正丁酯(TBT)在修饰后的乳胶粒表面进行水解与缩合,制备出了核壳结构PSt/TiO2复合微球,利用电镜对复合微球的结构形态进行了表征.结果表明,PSt乳液改性时体系的zeta电位随着PEI用量的增加而升高,当PEI用量为PSt聚合物重量的15%时,体系的zeta电位从原来的-40.3 mV升高到了38.3 mV,达到对PSt乳胶粒表面改性的最佳值;在制备PSt/TiO2复合微球时,TiO2包覆量随着反应时间的延长而增加,反应7 h时达到90.2%的最大值;随介质中水含量的增加,吸附到复合微球表面上的TiO2纳米颗粒逐渐减少,复合微球表面逐渐变得光滑,当EtOH/H2O质量比为100/6.0时,得到结构均一、壳层厚度为29 nm的核壳结构PSt/TiO2复合微球.